New cocktail of drugs shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT06967155
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study is testing a combination of four drugs (irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab) as a second treatment option for people with advanced colorectal cancer that has spread and has a specific BRAF gene mutation. The goal is to see if this mix can shrink tumors or slow the disease. About 23 adults are taking part, and the study will track their progress for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blokhin's Russian Cancer Research Center
Moscow, Moscow, 115478, Russia
Conditions
Explore the condition pages connected to this study.